Literature DB >> 10525827

Serum levels of thrombopoietin, IL-11, and IL-6 in pediatric thrombocytopenias.

M Cremer1, H Schulze, G Linthorst, C C Folman, S Wehnert, G Strauss, A E von dem Borne, K Welte, M Ballmaier.   

Abstract

We measured serum levels of thrombopoietin (TPO), interleukin (IL)-11, and IL-6 in 90 different samples from 67 pediatric patients with thrombocytopenia (TP). The cytokine levels were determined by enzyme-linked immunosorbent assays (ELISA), and the biological activity of TPO was measured using a cell line transfected with human c-mpl. In patients with impaired megakaryocytopoiesis, as found in diseases such as aplastic anemia, amegakaryocytic TP, or TP with absent radii, we found TPO levels which were highly elevated compared with normal values (mean=261 AU/ml, n=52, vs. 22 AU/ml in healthy controls). In contrast, patients suffering from idiopathic thrombocytopenic purpura (mean=16 AU/ml, n=31) or platelet function defects (mean=23 AU/ml, n=7) demonstrated normal TPO levels. The biological activity tested in the bioassay correlated well with the ELISA data. However, sera of some patients with amegakaryocytic TP demonstrated a remarkably higher biological activity of TPO than expected from the ELISA data. Within the different groups there was no correlation between platelet counts and TPO levels. Only 27% of all samples had elevated levels of IL-11 (mean=450 pg/ml, n=20). Elevated IL-6 serum levels were detected in only 13% of all samples analyzed (mean=42 pg/ml, n=12). We conclude that megakaryocytopoiesis is regulated mainly by TPO, that it is dependent on the platelet and the megakaryocytic mass, and that IL-11 plays an additional role in supporting the platelet production. IL-6 does not appear to be up-regulated in children with thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525827     DOI: 10.1007/s002770050538

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  2 in total

1.  A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia.

Authors:  Shujie Wang; Renchi Yang; Ping Zou; Ming Hou; Depei Wu; Zhixiang Shen; Xijing Lu; Yan Li; Xiequn Chen; Ting Niu; Hui Sun; Li Yu; Zhao Wang; Yin Zhang; Naibai Chang; Gaokui Zhang; Yongqiang Zhao
Journal:  Int J Hematol       Date:  2012-06-30       Impact factor: 2.490

2.  Development of novel ultra-sensitive IL-11 target engagement assays to support mechanistic PK/PD modeling for an anti-IL-11 antibody therapeutic.

Authors:  Maria Myzithras; Siqi Lin; Legairre Radden; Cynthia Hess Kenny; Zheng Cai; Angus MacDonald; Ralph Binetti; Michael Marlow; Paul Fracasso; Glenn Gibson; Christina Bartlett; Julie Hawkins; Steven Hansel
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.